Back to products
Endometrial Cancer CDO1 / CELF4 dual-gene methylation

CISENDO®Endometrial Cancer Methylation Test (CDO1/CELF4)

World's first non-invasive endometrial cancer screening, filling a clinical gap

CDO1/CELF4 dual-gene methylation test using non-invasive sampling to replace invasive biopsy — the world's first non-invasive endometrial cancer screening, filling a clinical gap.

NMPA Registration No.
20243402610
Date Approved
2024.12

Recommended companion kits

Use the DNA Isolation and Purifying Kit (Beijing Medical Device No. 20210020) for DNA extraction and purification, followed by DNA Methylation-Lightning MagPrep (Beijing Medical Device No. 20200110) for bisulfite conversion.

Clinical Data

Robust clinical data support

Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.

Sensitivity (Endometrial Cancer)94.51%
Registered clinical trial
Specificity94.16%
Registered clinical trial
4,818cases
Registered clinical samples
12,000real-world cases
Multi-center study
Cervical exfoliated cells (non-invasive sampling)
Sample Type
Target Population

Who needs this test?

  • Women with abnormal uterine bleeding
  • Endometrial cancer screening for postmenopausal women
  • Endometrial pathology risk assessment for perimenopausal women
  • High-risk women scheduled for hysteroscopy
Clinical Scenarios

How is it applied clinically?

  • Non-invasive early screening for endometrial cancer
  • Pre-hysteroscopy risk stratification to reduce unnecessary invasive procedures
  • Follow-up and monitoring for high-risk populations
  • Women's health screening programs at health checkup centers
Highlights

Why choose us

01

World's first non-invasive endometrial cancer methylation test

02

Global patents, CE certification, and Malaysia registration

03

Recommended by the Chinese Expert Consensus on Three-Tier Prevention Strategies for Endometrial Cancer

04

Recommended by the Expert Consensus on Clinical Application of Gene Methylation Screening for Endometrial Cancer

FAQ

Frequently asked questions about this test

What is the CISENDO test?

CISENDO is a Class III in vitro diagnostic device (NMPA Reg. No. 20243402610) that detects CDO1/CELF4 dual-gene methylation in cervical exfoliated cells — the world's first non-invasive endometrial cancer screening test.

How accurate is the CISENDO test?

Registration clinical trial data (4,818 samples) show 94.51% sensitivity for endometrial cancer and 94.16% specificity, supported by a 12,000-sample real-world multi-center study.

Can CISENDO replace hysteroscopy or endometrial biopsy?

CISENDO is a non-invasive screening tool using cervical exfoliated cells to assess endometrial cancer risk and reduce unnecessary invasive procedures. Definitive diagnosis still requires hysteroscopy/biopsy pathology, but CISENDO serves as an efficient first-line risk stratifier.

Why test methylation for abnormal uterine bleeding?

Abnormal uterine bleeding is the most common presenting symptom of endometrial cancer. Methylation testing non-invasively assesses malignancy risk, helping clinicians decide whether further invasive examination is needed — avoiding both delay and over-investigation.

Who is suitable for the CISENDO test?

Women with abnormal uterine bleeding, postmenopausal women, perimenopausal women at risk of endometrial lesions, and high-risk women scheduled for hysteroscopy.

Next step

Request the IFU, clinical summary and pricing

Tell us your institution type and intended use. We reply within 1–2 business days with the documents below, and can arrange a technical call with our clinical team.

  • IFU, registration certificate and sample requirements
  • Clinical performance summary and published papers
  • Distributor terms, kit configuration and logistics
Evidence

Endometrial Cancer Related Publications